Drug firm Jenburkt Pharmaceuticals on Friday announced that it has launched antiviral drug Favipiravir under the brand name ‘Favivent’. It is going to be available for treatment of COVID19 symptoms and is priced at Rs 39 per tablet. The tablet will be available in 200 mg strength in the form of a strip 10 tablet, it added.
The drug is going to be manufactured at a pharmaceutical plant in Telangana. THe company has ensured that the highest safety and manufacturing protocols will be followed. On Thursday, pharma company Brinton Pharmaceuticals had announced that it is going to be selling the tablet under the brand name ‘Faviton’ for the price of Rs. 59 per tablet.
Glenmark Pharmaceuticals is already selling the drug under the brand name ‘FabiFlu’ at a price of Rs 75 per tablet. Earlier, the Drug Controller General of India (DCGI) had approve the usage of this drug to treat COVID19. This tablet was developed in Japan and is most commonly used for treating influenza.
"Given the current scenario of grave health concerns and economic challenges surrounding COVID-19 in India, if we as a pharmaceutical company cannot make a significant positive difference to the society, our company's very existence is inconsequential," Jenburkt Pharmaceuticals Chairman and MD Ashish U Bhuta told CNN News 18.
“The company hopes that the easy accessibility and affordable price point of an effective treatment such as Favivent will offer Indian citizens a timely, much-needed therapeutic solution,” he added.
Cipla too has received regulatory approval to sell the anti-viral drug. “Cipla said it would launch favipiravir as "Ciplenza" in the first week of August, priced at Rs 68 (91 cents) per 200 mg tablet,” NDTV reported
OTHER NEWS SHOTS
